3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
21
Capecitabine
20
Fluorouracil
11
Leucovorin
9
Irinotecan
9
130-nm albumin-bound paclitaxel
8
durvalumab
6
Taxes
5
Radiotherapy
5
Platinum
4
Immunohistochemistry
4
Erlotinib Hydrochloride
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
trifluridine tipiracil drug combination
3
Trastuzumab
3
Sorafenib
3
Observation
3
Epirubicin
3
Drug Therapy
3
tremelimumab
2
toripalimab
2
regorafenib
2
pembrolizumab
2
anlotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gallbladder Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled